查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1474896

核准的藥物測試 (LDT) 市場規模、佔有率、趨勢分析報告：按技術、按應用、按地區、細分市場預測，2024-2030 年

Laboratory Developed Tests Market Size, Share & Trends Analysis Report By Technology (Immunoassay, Molecular Diagnostics), By Application (Oncology, Nutritional & Metabolic Disease), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

核准藥物檢測 (LDT) 市場的成長和趨勢：

Grand View Research, Inc.最新報告預測，到2030年，全球核准藥物試驗（LDT）開發市場規模將達到198.5億美元，2024年至2030年複合年成長率為7.05%。

該行業的成長得益於慢性病、遺傳疾病、感染疾病和自體免疫疾病的日益流行，以及人們健康生活意識的不斷增強。核准藥物測試 (LDT) 最常用於分子診斷，除了遺傳學之外，還包括各種不同化學物質的測試。

例如，2022年7月，Quest Diagnostics推出了基於實驗室的分子診斷測試，用於診斷猴痘病毒感染。此外，由於新測試的開發，免疫測量正在獲得廣泛的採用和接受。例如，2021 年 12 月，OPKO Health, Inc. 宣布 FDA 批准 4Kscore 測試，這是一種 LDT，將四種免疫檢測整合為一個數字評分，並考慮了患者年齡、切片檢查和已公佈的直腸核准檢結果。 LDT 不需要 FDA核准，因為它們不出售給其他人，但它們必須經過嚴格的驗證程序。然而，全球癌症盛行率的增加是推動該產業成長的關鍵因素。

根據 GLOBOCAN 估計，2020 年全球預計將新增 1,930 萬癌症病例，其中 230 萬是乳癌病例。肺癌是癌症患者最常見的死亡原因，因此該領域對更快、更準確的診斷工具的需求尚未得到滿足。 2021 年 1 月，英國體外診斷協會要求英國 NHS 開發癌症分子診斷的委託框架。主要企業正專注於產品發布和地理擴張，以獲取更高的行業佔有率。例如，2022 年 5 月，Guardant Health 推出了 Shield，這是一种血液檢測，可用作 LDT，以檢測 45 歲及以上成年人口中結直腸癌的早期跡象。

核准藥物測試 (LDT) 市場報告重點：

  • 分子診斷技術領域在該行業中佔據主導地位，並在 2023 年佔整體銷售額的最大佔有率。
  • 該領域的成長是由於對許多疾病提供診斷測試的需求增加。
  • 由於癌症盛行率的增加，預計癌症應用領域在預測期內將顯著成長。
  • 由於創新服務的推出可以滿足目標受眾不斷成長的需求，預計該市場將大幅成長。
  • 由於新型LDT產品的推出以及老年人口不斷成長對診斷工具的高需求，北美將在2023年佔據該行業的主導地位。

目錄

第1章核准的藥物測試（LDT）市場：調查方法與範圍

第 2 章核准的藥物測試 (LDT) 市場：執行摘要

  • 市場展望
  • 分部展望
  • 競爭考察

第3章核准藥物測試 (LDT) 市場：變數、趨勢、範圍

  • 市場體系展望
  • 市場動態
  • 核准的藥物測試（LDT）市場分析工具

第4章核准的藥物測試（LDT）市場：技術評估和趨勢分析

  • 2023年及2030年技術市場佔有率
  • 細分儀表板
  • 全球核准藥物測試（LDT）市場，按技術分類的前景
  • 2018-2030年市場規模、預測及趨勢分析

第5章核准的藥物測試（LDT）市場：應用估算和趨勢分析

  • 2023年及2030年應用市場佔有率
  • 細分儀表板
  • 全球核准藥物測試（LDT）市場，依應用前景
  • 2018-2030年市場規模、預測及趨勢分析

第6章核准的藥物測試（LDT）市場：區域估計和趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030年市場規模、預測及趨勢分析
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • Quest Diagnostics Incorporated.
    • 23andMe, Inc.
    • Abbott
    • Guardant Health
    • NeoGenomics Laboratories.
    • QIAGEN
    • Siemens Healthineers AG
    • Illumina, Inc.
    • F. Hoffmann-La Roche Ltd.
Product Code: GVR-4-68040-010-5

Laboratory Developed Tests Market Growth & Trends:

The global laboratory developed tests market size is expected to reach USD 19.85 billion by 2030, expanding at a CAGR of 7.05% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of the industry is attributed to the increasing prevalence of chronic and genetic diseases, infectious & autoimmune diseases, and rising awareness among the population about healthy living. The laboratory-developed tests (LDTs) are generated and utilized in the laboratories, and LDTs are released into the market without FDA approval or any other independent regulatory assessment. LDTs are most typically employed in molecular diagnostics, which includes tests that target a variety of different chemicals in addition to genetics.

For instance, in July 2022, Quest Diagnostics launched a lab-based molecular diagnostic test for the diagnosis of monkeypox virus infections. Moreover, immunoassay is gaining immense adoption and acceptability with the development of novel tests. For instance, in December 2021, OPKO Health, Inc., announced the FDA approval of the 4Kscore test, an LDT in which, four immunoassays are combined into a single numerical score that takes into account the patient's age, biopsy history, and the results of a digital rectal exam. Although LDTs do not require FDA approval as they are not marketed to others, they need to go through rigorous validation procedures. However, the increasing global prevalence of cancer is a key factor driving the industry's growth.

According to GLOBOCAN, in 2020, there were an estimated 19.3 million new cancer cases globally, out of which, 2.3 million were breast cancer cases. Lung cancer was the most common cause of death among cancer patients, representing an unmet need for faster and more accurate diagnostic tools in the segment. In January 2021, the British In Vitro Diagnostics Association urged NHS England for the development of a commissioning framework for molecular diagnostics in oncology. Key players focus on product launches and geographical expansion to gain a higher industry share. For instance, in May 2022, Guardant Health launched Shield, a blood test that is available as an LDT for the detection of early signs of colorectal cancer in the adult population aged above 45 years

Laboratory Developed Tests Market Report Highlights:

  • The molecular diagnostic technology segment dominated the industry and accounted for the largest share of the overall revenue in 2023
  • The segment growth was attributed to the increased need to provide diagnostics tests for a number of diseases
  • The oncology application segment is expected to grow lucratively over the forecast period due to the increasing prevalence of cancer
  • The market is expected to grow significantly owing to the introduction of innovative services that can address the growing demands of the target audience
  • North America dominated the industry in 2023 owing to the introduction of novel LDT products and the high demand for diagnostics tools with the increasing geriatric population

Table of Contents

Chapter 1. Laboratory Developed Tests Market: Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. Application
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Laboratory Developed Tests Market: Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Technology outlook
    • 2.2.2. Application outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Laboratory Developed Tests Market: Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing demand for in vitro diagnostic tests that are currently unavailable in the market
      • 3.2.1.2. Increasing demand for development of personalized medicine
      • 3.2.1.3. No requirement for any regulatory approval
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost associated with the laboratory-developed test
      • 3.2.2.2. Efficacy and safety issues related to LDT
  • 3.3. Laboratory Developed Tests (LDT) Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Laboratory Developed Tests (LDT) Market: Technology Estimates & Trend Analysis

  • 4.1. Technology Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Laboratory Developed Tests (LDT) Market by Technology Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Immunoassays
      • 4.4.1.1. Immunoassays market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Hematology and Coagulation
      • 4.4.2.1. Hematology and coagulation market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Molecular Diagnostics
      • 4.4.3.1. Molecular diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.4. Microbiology
      • 4.4.4.1. Microbiology market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.5. Clinical Chemistry
      • 4.4.5.1. Clinical chemistry market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.6. Histology/Cytology
      • 4.4.6.1. Histology/Cytology market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.7. Flow Cytometry
      • 4.4.7.1. Flow Cytometry market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.8. Mass Spectroscopy
      • 4.4.8.1. Mass spectroscopy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.9. Others
      • 4.4.9.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Laboratory Developed Tests (LDT) Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Laboratory Developed Tests (LDT) Market by Application Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Oncology
      • 5.4.1.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.2. Genetic Disorders/Inherited Disease
      • 5.4.2.1. Genetic disorders/Inherited disease market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.3. Infectious & Parasitic Diseases
      • 5.4.3.1. Infectious & parasitic diseases market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.4. Immunology
      • 5.4.4.1. Immunology market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.5. Endocrine
      • 5.4.5.1. Endocrine market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.6. Nutritional & Metabolic Disease
      • 5.4.6.1. Nutritional & metabolic disease market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.7. Cardiology
      • 5.4.7.1. Cardiology market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.8. Mental/Behavioral Disorder
      • 5.4.8.1. Mental/Behavioral disorder market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.9. Pediatrics-specific Testing
      • 5.4.9.1. Pediatrics-specific testing market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.10. Hematology/General Blood Testing
      • 5.4.10.1. Hematology/General blood testing market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.11. Bodily Fluid Analysis
      • 5.4.11.1. Bodily fluid analysis market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.12. Toxicology
      • 5.4.12.1. Toxicology market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.13. Other Diseases
      • 5.4.13.1. Other diseases market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Laboratory Developed Tests (LDT) Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.8.2. Mexico
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. Quest Diagnostics Incorporated.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. 23andMe, Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Abbott
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Guardant Health
      • 7.3.7.1. Company overview
      • 7.3.7.2. Product benchmarking
      • 7.3.7.3. Strategic initiatives
    • 7.3.8. NeoGenomics Laboratories.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. QIAGEN
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Siemens Healthineers AG
      • 7.3.10.1. Company overview
      • 7.3.10.2. Product benchmarking
      • 7.3.10.3. Strategic initiatives
    • 7.3.11. Illumina, Inc.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Product benchmarking
      • 7.3.11.3. Strategic initiatives
    • 7.3.12. F. Hoffmann-La Roche Ltd.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Product benchmarking
      • 7.3.12.3. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America laboratory developed tests market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 4 North America laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 5 U.S. laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 6 U.S. laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 7 Canada laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 8 Canada laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 9 Europe laboratory developed tests market, by region, 2018 - 2030 (USD Million)
  • Table 10 Europe laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 11 Europe laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 12 Germany laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 13 Germany laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 14 U.K. laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 15 U.K. laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 16 France laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 17 France laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 18 Italy laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 19 Italy laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 20 Spain laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 21 Spain laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 22 Denmark laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 23 Denmark laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 24 Sweden laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 25 Sweden laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 26 Norway laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 27 Norway laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific laboratory developed tests market, by region, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 31 China laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 32 China laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 33 Japan laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 34 Japan laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 35 India laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 36 India laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 37 South Korea laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 38 South Korea laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 39 Australia laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 40 Australia laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 41 Thailand laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 42 Thailand laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 43 Latin America laboratory developed tests market, by region, 2018 - 2030 (USD Million)
  • Table 44 Latin America laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 45 Latin America laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 46 Brazil laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 47 Brazil laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 48 Mexico laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 49 Mexico laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 50 Argentina laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 51 Argentina laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 52 MEA laboratory developed tests market, by region, 2018 - 2030 (USD Million)
  • Table 53 MEA laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 54 MEA laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 55 South Africa laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 56 South Africa laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 59 UAE laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 60 UAE laboratory developed tests market, by application, 2018 - 2030 (USD Million)
  • Table 61 Kuwait laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
  • Table 62 Kuwait laboratory developed tests market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Laboratory developed tests market: market outlook
  • Fig. 14 Tumor ablation competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Laboratory developed tests market driver impact
  • Fig. 20 Laboratory developed tests market restraint impact
  • Fig. 21 Laboratory developed tests market strategic initiatives analysis
  • Fig. 22 Laboratory developed tests market: Technology movement analysis
  • Fig. 23 Laboratory developed tests market: Technology outlook and key takeaways
  • Fig. 24 Immunoassays market estimates and forecast, 2018 - 2030
  • Fig. 25 Hematology and coagulation estimates and forecast, 2018 - 2030
  • Fig. 26 Molecular diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 27 Microbiology market estimates and forecast, 2018 - 2030
  • Fig. 28 Clinical chemistry market estimates and forecast, 2018 - 2030
  • Fig. 29 Histology/Cytology market estimates and forecast, 2018 - 2030
  • Fig. 30 Flow cytometry market estimates and forecast, 2018 - 2030
  • Fig. 31 Mass spectroscopy market estimates and forecast, 2018 - 2030
  • Fig. 32 Others market estimates and forecast, 2018 - 2030
  • Fig. 33 Laboratory developed tests market: Application movement Analysis
  • Fig. 34 Laboratory developed tests market: Application outlook and key takeaways
  • Fig. 35 Oncology market estimates and forecasts, 2018 - 2030
  • Fig. 36 Genetic disorders/Inherited disease market estimates and forecasts, 2018 - 2030
  • Fig. 37 Infectious & parasitic diseases market estimates and forecasts, 2018 - 2030
  • Fig. 38 Immunology market estimates and forecasts, 2018 - 2030
  • Fig. 39 Endocrine market estimates and forecasts, 2018 - 2030
  • Fig. 40 Nutritional & metabolic disease market estimates and forecasts, 2018 - 2030
  • Fig. 41 Cardiology market estimates and forecasts, 2018 - 2030
  • Fig. 42 Mental/Behavioral disorder market estimates and forecasts, 2018 - 2030
  • Fig. 43 Pediatrics-specific testing market estimates and forecasts, 2018 - 2030
  • Fig. 44 Hematology/General blood testing market estimates and forecasts, 2018 - 2030
  • Fig. 45 Bodily fluid analysis market estimates and forecasts, 2018 - 2030
  • Fig. 46 Toxicology market estimates and forecasts, 2018 - 2030
  • Fig. 47 Other diseases market estimates and forecasts, 2018 - 2030
  • Fig. 48 Global laboratory developed tests market: Regional movement analysis
  • Fig. 49 Global laboratory developed tests market: Regional outlook and key takeaways
  • Fig. 50 Global laboratory developed tests market share and leading players
  • Fig. 51 North America market share and leading players
  • Fig. 52 Europe market share and leading players
  • Fig. 53 Asia Pacific market share and leading players
  • Fig. 54 Latin America market share and leading players
  • Fig. 55 Middle East & Africa market share and leading players
  • Fig. 56 North America: SWOT
  • Fig. 57 Europe SWOT
  • Fig. 58 Asia Pacific SWOT
  • Fig. 59 Latin America SWOT
  • Fig. 60 MEA SWOT
  • Fig. 61 North America market estimates and forecasts, 2018 - 2030
  • Fig. 62 U.S key country dynamics
  • Fig. 63 U.S market estimates and forecasts, 2018 - 2030
  • Fig. 64 Canada key country dynamics
  • Fig. 65 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 66 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 67 UK key country dynamics
  • Fig. 68 UK market estimates and forecasts, 2018 - 2030
  • Fig. 69 Germany key country dynamics
  • Fig. 70 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 71 France key country dynamics
  • Fig. 72 France market estimates and forecasts, 2018 - 2030
  • Fig. 73 Italy key country dynamics
  • Fig. 74 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 75 Spain key country dynamics
  • Fig. 76 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 77 Denmark key country dynamics
  • Fig. 78 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 79 Sweden key country dynamics
  • Fig. 80 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 81 Norway key country dynamics
  • Fig. 82 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 83 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 84 China key country dynamics
  • Fig. 85 China market estimates and forecasts, 2018 - 2030
  • Fig. 86 Japan key country dynamics
  • Fig. 87 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 88 India key country dynamics
  • Fig. 89 India market estimates and forecasts, 2018 - 2030
  • Fig. 90 Thailand key country dynamics
  • Fig. 91 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 92 South Korea key country dynamics
  • Fig. 93 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 94 Australia key country dynamics
  • Fig. 95 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 96 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 97 Brazil key country dynamics
  • Fig. 98 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 99 Mexico key country dynamics
  • Fig. 100 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 101 Argentina key country dynamics
  • Fig. 102 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 103 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 104 South Africa key country dynamics
  • Fig. 105 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 106 Saudi Arabia key country dynamics
  • Fig. 107 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 108 UAE key country dynamics
  • Fig. 109 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 110 Kuwait key country dynamics
  • Fig. 111 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 112 Market share of key market players- Laboratory developed tests market